Fewer Life Sciences Co. Investor Suits Lodged In 2011

Law360, New York (March 21, 2012, 4:36 PM EDT) -- Securities fraud class actions lodged against life sciences companies dropped by more than 40 percent in 2011, fueled by a decline of suits stemming from the global financial crisis, according to a Dechert LLP report released Tuesday.

The annual report said 17 securities fraud class actions were filed against pharmaceutical, biotechnology and medical device companies and their officials and directors in 2011, down from 29 in 2010. They represented just 9 percent of the 188 securities class actions filed against public companies in 2011, the lowest...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.